Cellebrite DI [CLBT] vs Nutanix [NTNX] Detailed Stock Comparison

Cellebrite DI Ltd.

NASDAQ
Loading...

Nutanix, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Cellebrite DI Ltd. wins in 9 metrics, Nutanix, Inc. wins in 11 metrics, with 0 ties. Nutanix, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Cellebrite DI Ltd. Nutanix, Inc. Better
P/E Ratio (TTM) 42.90 37.40 Nutanix, Inc.
Price-to-Book Ratio 6.83 -11.11 Cellebrite DI Ltd.
Debt-to-Equity Ratio 4.68 -1.86 Cellebrite DI Ltd.
PEG Ratio 3.43 0.46 Nutanix, Inc.
EV/EBITDA 37.06 29.87 Nutanix, Inc.
Profit Margin (TTM) 16.47% 9.95% Cellebrite DI Ltd.
Operating Margin (TTM) 16.15% 11.64% Cellebrite DI Ltd.
EBITDA Margin (TTM) 16.15% 11.64% Cellebrite DI Ltd.
Return on Equity 19.10% -27.12% Cellebrite DI Ltd.
Return on Assets (TTM) 5.10% 4.44% Cellebrite DI Ltd.
Free Cash Flow (TTM) $160.32M $750.17M Nutanix, Inc.
1-Year Return -11.69% -32.10% Cellebrite DI Ltd.
Price-to-Sales Ratio (TTM) 6.97 3.46 Nutanix, Inc.
Enterprise Value $2.90B $8.80B Nutanix, Inc.
EV/Revenue Ratio 6.10 3.28 Nutanix, Inc.
Gross Profit Margin (TTM) 84.71% 87.37% Nutanix, Inc.
Revenue per Share (TTM) $2 $10 Nutanix, Inc.
Earnings per Share (Diluted) $0.31 $0.92 Nutanix, Inc.
Beta (Stock Volatility) 1.28 0.52 Nutanix, Inc.
Short % of Float 3.52% 6.25% Cellebrite DI Ltd.

Cellebrite DI Ltd. vs Nutanix, Inc. Stock Performance Analysis

Loading Price Chart...

CLBT
NTNX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Cellebrite DI Ltd.-5.34%11.65%3.96%3.20%-21.22%-20.52%
Nutanix, Inc.-1.13%10.51%23.98%29.24%10.34%2.91%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Cellebrite DI Ltd.-11.69%157.97%48.79%52.48%52.48%52.48%
Nutanix, Inc.-32.10%70.44%55.53%40.73%40.73%40.73%

Performance & Financial Health Analysis: Cellebrite DI Ltd. vs Nutanix, Inc.

MetricCLBTNTNX
Market Information
Market Cap i$3.18B$9.30B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i2,014,3913,690,740
90 Day Avg. Volume i1,712,4944,718,617
Last Close$14.18$72.76
52 Week Range$11.02 - $19.98$43.35 - $83.36
% from 52W High-29.03%-12.72%
All-Time High$26.30 (Feb 03, 2025)$83.36 (May 19, 2025)
% from All-Time High-46.08%-12.72%
Growth Metrics
Quarterly Revenue Growth0.18%0.10%
Quarterly Earnings Growth0.10%0.83%
Financial Health
Profit Margin (TTM) i0.16%0.10%
Operating Margin (TTM) i0.16%0.12%
Return on Equity (TTM) i0.19%-0.27%
Debt to Equity (MRQ) i4.68-1.86
Cash & Liquidity
Book Value per Share (MRQ)$1.95$-3.13
Cash per Share (MRQ)$1.75$7.07
Operating Cash Flow (TTM) i$173.54M$832.21M
Levered Free Cash Flow (TTM) i$140.94M$664.85M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Cellebrite DI Ltd. vs Nutanix, Inc.

MetricCLBT (Apr 24, 2026)NTNX (Apr 13, 2026)
Price Ratios
P/E Ratio (TTM) i42.9037.40
Forward P/E i21.8015.95
PEG Ratio i3.430.46
Price to Sales (TTM) i6.973.46
Price to Book (MRQ) i6.83-11.11
Market Capitalization
Market Capitalization i$3.18B$9.30B
Enterprise Value i$2.90B$8.80B
Enterprise Value Metrics
Enterprise to Revenue i6.103.28
Enterprise to EBITDA i37.0629.87
Risk & Other Metrics
Beta i1.280.52
Book Value per Share (MRQ) i$1.95$-3.13

Financial Statements Comparison: Cellebrite DI Ltd. vs Nutanix, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCLBT (2025)NTNX (2025)
Revenue/Sales i475.68M2.54B
Cost of Goods Sold i75.17M334.78M
COGS % of Revenue i15.8%13.2%
Gross Profit i400.50M2.20B
Gross Margin i84.2%86.8%
Research & Development i113.88M736.82M
Operating Income (EBIT) i66.48M172.54M
Operating Margin i14.0%6.8%
EBITDA i102.33M292.73M
EBITDA Margin i21.5%11.5%
Pre-Tax Income i90.68M211.65M
Pre-Tax Income % of Revenue i19.1%8.3%
Income Tax i12.35M23.28M
Income Tax % of Revenue i2.6%0.9%
Net Income (Profit) i78.33M188.37M
Profit Margin i16.5%7.4%

Balance Sheet & Liquidity Metrics

MetricCLBT (2025)NTNX (2025)
Cash & Equivalents i124.46M769.50M
Total Current Assets i575.85M2.59B
Total Current Assets % of Revenue i121.1%102.0%
Total Current Liabilities i369.66M1.41B
Total Current Liabilities % of Revenue i77.7%55.7%
Long-Term Debt i18.67M1.46B
Long-Term Debt % of Revenue i3.9%57.5%
Total Shareholders Equity i484.32M-694.52M
Retained Earnings i-86.54M-4.90B
Retained Earnings % of Revenue i-18.2%-192.9%
Property, Plant & Equipment i16.95M276.54M

Cash Flow Statement Comparison

MetricCLBT (2025)NTNX (2025)
Operating Cash Flow i163.74M800.54M
Operating Cash Flow % of Revenue i34.4%31.5%
Capital Expenditures i-13.23M-71.28M
Free Cash Flow i160.32M750.17M
FCF Margin i33.7%29.6%
Debt Repayment iN/A-102.88M
Common Stock Repurchase iN/A-307.90M

Short Interest & Institutional Ownership Analysis

MetricCLBTNTNX
Shares Short i4.91M12.17M
Short Ratio i2.882.01
Short % of Float i3.52%6.25%
Shares Outstanding i248.58M265.63M
Float Shares i122.90M263.51M
% Held by Insiders i43.14%0.44%
% Held by Institutions i53.29%93.66%
% Held by Public i3.57%5.90%

Dividend Analysis & Yield Comparison: Cellebrite DI Ltd. vs Nutanix, Inc.

MetricCLBTNTNX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A